Bcl-2-interacting killer (BIK)

Bcl-2-interacting killer (BIK) is a pro-apoptotic member of the BCL2 protein family, classified as a BH3-only protein. It functions by binding to and antagonizing anti-apoptotic proteins such as BCL2 and BCL-xL, thereby promoting programmed cell death (apoptosis) through mitochondrial outer membrane permeabilization and cytochrome c release. BIK plays a critical role in the intrinsic apoptosis pathway, and its deregulation has been implicated in cancer and resistance to cell death. Originally identified as a target for anti-apoptotic proteins, BIK is not a direct target of any approved therapeutic drugs, but as a member of the apoptosis-regulating network, it is important in cancer biology and is a potential target for future drug development[1][3].

Other names

Bcl-2-interacting killerBIKNBKApoptosis inducer NBKBIP1BP4natural born killerbcl-2-interacting killerBCL2-interacting killer (apoptosis-inducing)

Induction of apoptosis via direct binding to and neutralization of anti-apoptotic BCL-2 family proteins (e.g., BCL-2, BCL-xL) through its BH3 domain, promoting mitochondrial outer membrane permeabilization and cytochrome c release[1][3].